For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250602:nRSB8755Ka&default-theme=true
RNS Number : 8755K Tristel PLC 02 June 2025
TRISTEL plc
("Tristel" or the "Company")
Investor Presentations and Notice of Trading Update
Capital Markets Day & Shareholder Open Day
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces it will host two investor presentations on consecutive days, Tuesday
29 July 2025 and Wednesday 30 of July 2025. Both sessions will feature the
same presentations, offer a chance to meet the Senior Leadership Team, include
insights from a US customer using Tristel ULT, familiarise themselves with the
Company's products and provide an open forum for questions. Details of the two
events are below.
Capital Markets Day
The Capital Markets Day will be hosted in the City of London on Tuesday 29
July 2025. The event will commence at 14:30pm BST and welcomes Institutional
Investors and Analysts. For more information and to register please contact
Walbrook PR via tristel@walbrookpr.com.
Shareholder Open Day
The Shareholder Open Day will be hosted at the Company's headquarters in
Snailwell, Cambridgeshire on Wednesday 30 July 2025. Shareholders are welcome
from 12:00pm BST. Along with the presentations detailed above, it will also
provide an opportunity for shareholders take a tour of the facility.
Availability is limited so please contact Walbrook PR
via tristel@walbrookpr.com or call 020 7933 8780 to reserve an entry ticket.
For those that are unable to make the above presentations in person, a
recording will be made available on the Company's website, shortly after the
event, here: https://tristelgroup.com/invest/webinars-presentations/
(https://tristelgroup.com/invest/webinars-presentations/) .
No new material information regarding current trading will be disclosed during
the day.
Notice of Trading Update
The Company will also provide an update on trading for the year ended 30 June
2025 on Tuesday 29 July 2025.
For further information please contact:
Tristel plc Via Walbrook PR
Matt Sassone, Chief Executive Officer www.investors.tristel.com (http://www.investors.tristel.com/)
Liz Dixon, Chief Financial Officer
Walbrook PR Ltd Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus / Lianne Applegarth / Alice Woodings Mob: 07980 541 893/ 07584 391 303/ 07407 804 654
Cavendish Capital Markets Ltd Tel: 020 7220 0500
Geoff Nash / Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)
About Tristel plc
Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.
Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25% and the
business is profitable, with no debt and has a progressive dividend policy.
The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).
For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCAMMFTMTBJBJA